Piramal Pharma wants to be a $2 billion global firm by 2030, analysts give 5-year plan a thumbs up

Brokerages are optimistic about Piramal Pharma’s growth. Jefferies and Motilal Oswal have given it a ‘buy’ rating and with a target price to ₹260.

Brokerages are optimistic about Piramal Pharma’s growth. Jefferies and Motilal Oswal have given it a ‘buy’ rating and with a target price to ₹260.

Kotak said that NTPC Green Energy’s proposed equity raise of ₹10,000 crore will likely suffice for the equity contribution for 11.7 GW of the incremental capacity addition.

Upon the scheme becoming effective, shareholders of Delta Corp will get one share of Delta Penland Private Ltd. for every share held in Delta Corp.

UBS highlighted in its note that there is a potential sales risk to Real juices in India on the impact of a carbonated soft drink price war.

Manish Gunwani, CIO of Bandhan AMC does not expect massive earnings surprises from the financial sector.

Gold prices rise: This surge has been fueled by several global economic and geopolitical factors.

Despite this recent surge, shares of Exxaro Tiles are underperformers in 2024, having declined 12% so far this year.

This decision is part of SEBI’s effort to make the process more efficient and align it with the existing process for public issues of equity shares and convertibles.

Bernstein in its note mentioned that a potential surprise in microfinance credit costs for IndusInd Bank could create better buying chances in the near term.

EaseMyTrip Share Price | On Tuesday, September 24, sources told CNBC-TV18 that the company’s promoter Nishant Pitti was to sell up to 8.5% of his stake in the company via block deals, with an estimated block size of ₹622 crore.